Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Paris based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Sylvain Cascarino
CFO of Kurma Partners
More than 15 years of experience in Finance & Administration. Previously entrepreneur and CFO for Nekazen/Le MAG VoD. Fund controller & Internal Auditor for Jones Lang LaSalle. Tax Advisor with Arthur Andersen. Sylvain joined Kurma in January 2013.
Follow Sylvain Cascarino:
About Kurma Partners: Kurma Partners is a management company specializing in the financing of innovation in healthcare and biotechnology.
Thomas Gidoin
CFO of GenSight Biologics
Thomas Gidoin has been GenSight Biologics’ Chief Financial Officer since June 2015. From 2012 to mid-2015, Thomas was Vice President Finance at DBV Technologies S.A., where he led the Corporate Finance team and participated in public offerings and private placements, including the dual listing of DBV Technologies on the Nasdaq Global Select Market in 2014. From 2008 to 2011, he served in various positions at Ipsen S.A., including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young. Thomas received a Master’s degree in International Finance from ESGF Paris and a Master’s degree in International Management from Neoma Business School in France.
Follow Thomas Gidoin:
About GenSight Biologics: GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
Christelle Dumoussaud
Chief Financial Officer of ENTEROME
Christelle Dumoussaud has served as our Chief Financial Officer since 2015. Ms. Dumoussaud has more than 20 years’ experience in financial departments of various industries. In 2015, Ms. Dumoussaud served as General Secretary at Laboratoire Hepatoum-Dermophil Indien and Ms. Dumoussaud served as a financial consultant at Expert & Consult in 2014. From 2012 to 2013, Ms. Dumoussaud served as Administration and Finance Manager at Almavia and from 2007 to 2012, Ms. Dumoussaud served as General Secretary at Polygon/Munters France-Belgium. Ms. Dumoussaud worked at Fournier/Solvay Pharma from 1997 to 2007, serving as the Finance Director from 2005 to 2007. Ms. Dumoussaud served as the Chief Financial Officer of Fournier Pharma Belgium from 2001 to 2004. Ms. Dumoussaud holds a Master in Business Management from the ISC Paris.
Follow Christelle Dumoussaud:
About ENTEROME: Enterome is a clinical-stage company developing drugs for chronic medical conditions relating to abnormalities of bacterial composition.
Eric Cohen
CFO of Acticor Biotech
CEO and Founder of Agile Capital Markets; Advisor of several biotech & medtech companies (among which EOS imaging, Cellnovo, PKvitality), Eric raised over 200M€ in public and private fund raising. He was previously CFO of Mauna Kea Technologies (Euronext®: MKEA), Hybrigenics (Euronext®: ALHYG) and Teva Pharmaceuticals France (NASDAQ®: TLV). He led 2 IPO on Euronext® raising 62M€. He was also Head of Hybrigenics Business Services and Head of Operations (R&D and Production) at Mauna Kea Technologies.
Follow Eric Cohen:
About Acticor Biotech: Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke.
Jérôme Vailland
Chief Financial Officer of Coave Therapeutics
Jérôme VAILLAND has 15 years of experience in audit, management, and transactions, and joined HORAMA CFO in November 2016. He began his career as a Financial Controller at Bouygues Telecom, and was subsequently hired as a Senior Manager by Ernst & Young, where he worked for 11 years in the fields of financial auditing, transaction advisory services, and IPO services, mainly in the life sciences industry, in addition to his managerial duties (team management, business development, recruitment, etc.). Jérôme is a graduate of Audencia-Nantes, where he majored in audit-financial control.
Follow Jérôme Vailland:
About Coave Therapeutics: Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Erwan Martin
Chief Financial Officer of CellNovo
Erwan brings over 20 years of experience in finance, biotechnology and corporate development. Before joining Cellnovo, Erwan was Chief Financial Officer of Genomic Vision (Euronext: GV), a position he had held since 2009. He was also VP of Corporate Development until 2015, undertaking financing operations such as the Company’s initial public offering. He has also worked at Syndex, and co-founded Cytomics Pharmaceuticals, a biotechnology company specialising in the discovery of new medicines.
Follow Erwan Martin:
About CellNovo: CellNovo is a medical device company developing a wireless therapeutic system for diabetic patients.
Bertrand Devillers
CFO of Fermentalg
Bertrand Devillers is the chief financial officer of Fermentalg.
Follow Bertrand Devillers:
About Fermentalg: Fermentalg is engaged in the production of micro-algae for the agrifood, healthcare and energy markets.
Gordon Waldron
Chief Financial Officer of Antabio
Gordon Waldron is the Chief Financial Officer at Antabio. Prior to joining SuperSonic Imagine in September 2010, Mr. Waldron spent five years as CFO for the French biotech company Novexel where he raised €50 million in 2006, negotiated a preclinical license agreement which brought the company a €75 million upfront payment in 2008 and directed a trade sale process resulting in the acquisition of Novexel by AstraZeneca for cash consideration of approximately $500 million in 2009. Before Novexel, he spent eight years as VP Finance with Synt:em (Nimes, France) where he raised €32 million in three financing rounds. Gordon also spent five years with Texas Instruments, first as Finance Director for a French subsidiary, then as Group Finance Manager (based in the UK) covering 17 entities and a distributor network for Texas Instruments Software in the Europe, Middle East and Africa territories. Mr. Waldron started his career with Spie Batignolles at its head office near Paris before becoming a controller of the company’s US subsidiaries based in Pittsburgh. He graduated from Duke University (USA) in 1988 and has both American and British nationalities.
Follow Gordon Waldron:
About Antabio, SuperSonic Imagine: Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in areas of highest medical need.
Laurent Guy
CFO of AB Science
Follow Laurent Guy:
About AB Science: AB Science is a pharmaceutical company specializing in drugs use tyrosine kinase inhibitors.
Laurent Guy
CFO of AB Science
Follow Laurent Guy:
About AB Science: AB Science is a pharmaceutical company specializing in drugs use tyrosine kinase inhibitors.
Anne Renevot
Chief Financial Officer of Poxel
Prior to joining Poxel, Anne Renevot served as CFO of EOS Imaging where she played a key role in EOS’ successful IPO on Euronext Paris, which raised €39M. At EOS Imaging, Ms. Renevot helped to raise capital through private placements, equity lines and debt offerings. She was responsible for financial regulatory compliance, financial planning and communications, and she also held leading roles in the Company’s acquisitions and partnerships. Before her appointment at EOS Imaging, Ms. Renevot served at Cartier, a luxury goods company, as CFO of Cartier Joaillerie Manufacturing Division and as International Financial Controller. Earlier in her career, Ms. Renevot served as Manager at EY Audit and as a Division Controller at Legris Industries. Anne Renevot received a bachelor’s degree in finance from Audencia Business School in Nantes, France and a master’s degree in corporate finance from Ohio State University, Columbus, Ohio.
Follow Anne Renevot:
About Poxel: Poxel is a research integrated pharmaceutical company that develops products for metabolic diseases.
Susanne Liepmann
Group CFO of HTL Biotechnology
Follow Susanne Liepmann:
About HTL Biotechnology: HTL Biotechnology is a manufacturer and research & development of Hyaluronan and other biological polymers by bacterial fermentation.
Sebastien Robitaille
Chief of Staff and Interim Chief Financial Officer of DBV Technologies
Sébastien Robitaille serves as Chief of Staff to the CEO and Deputy Chief Financial Officer, responsible for overseeing the global collective success drivers for the Company, leading the transformation from a development-stage biotechnology company to a potential commercial organization. He oversees Finance and Information Systems at Group level, and is a member of the Executive Committee. Mr. Robitaille brings extensive experience in the pharmaceutical industry and deep knowledge of performance management, forecasting and business modelling, transformation programs and implementation of strategic information systems. Mr. Robitaille joined DBV in 2015 as Senior Vice President, Group Controller & Information Systems and was subsequently named Deputy Chief Financial Officer. Prior to DBV, he worked at Ipsen for 15 years where he held various roles of increasing responsibility and participated in the company’s IPO. Mr. Robitaille received his Bachelor’s Degree in Business Administration-Finance from Paris School of Business.
Follow Sebastien Robitaille:
About DBV Technologies: DBV Technologies focuses on the development of innovative products for the diagnosis and treatment of food allergies.
Christophe Lamboeuf
Chief Financial Officer of Mauna Kea Technologies
Prior to joining Mauna Kea Technologies, Christophe Lamboeuf served as the Chief Financial Officer and Deputy Chief Executive Officer of Intrasense, a French publicly-traded company developing a medical imaging visualization and analysis software suite. He was involved in a number of capital raises following the company’s initial public offering in 2012. He also has experience working with General Electric, Ricoh, CS Telecom and Toshiba. Christophe is a chartered accountant and holds an advanced degree (DESS) in Finance from the IAE Graduate School of Management and a Master in Economics.
Follow Christophe Lamboeuf:
About Mauna Kea Technologies: Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools.
Baptiste Billoir
Co-Founder and CFO of AgenT
Follow Baptiste Billoir:
About AgenT: AgenT develops the first blood diagnosis to detect Alzheimer’s years before the onset of the irreversible symptoms.
Jean-Pierre Adiceom
CFO of Bioaxial
Jean-Pierre Adiceom currently serves BioAxial as CFO.
Follow Jean-Pierre Adiceom:
About Bioaxial, Sanofi: Bioaxial develops new technologies for fluorescence microscopy to improve extended imaging of live cells.
